Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept vs Ranibizumab for Macular Edema in BRVO
NCT03709745Phase 4Completed
- Sponsor
- St. Eriks Eye Hospital
- Start
- Oct 2018
- Primary completion
- Oct 2021
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept, ranibizumab in branch retinal vein occlusion (BRVO), macular edema, sponsored by St. Eriks Eye Hospital. Started Oct 2018; status: completed.
02
Drugs
afliberceptranibizumab
03
Conditions
branch retinal vein occlusion (BRVO)macular edema
Beyond the preview
Go deeper on NCT03709745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03709745.